Skip Navigation


European Heart Journal Advance Access originally published online on March 26, 2009
European Heart Journal 2009 30(10):1222-1228; doi:10.1093/eurheartj/ehp087
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
30/10/1222    most recent
ehp087v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yamagishi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamagishi, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

A genetic variant on chromosome 9p21 and incident heart failure in the ARIC study

Kazumasa Yamagishi1,2, Aaron R. Folsom1,*, Wayne D. Rosamond3, Eric Boerwinkle4 for the ARIC Investigators

1 Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1300 S Second Street, Suite 300, Minneapolis, MN 55454-1015, USA
2 Department of Public Health Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
3 Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, USA
4 Human Genetics Center and Institute for Molecular Medicine, University of Texas Health Science Center, Houston, TX, USA

Received 27 June 2008; revised 5 February 2009; accepted 18 February 2009; online publish-ahead-of-print 26 March 2009.

* Corresponding author. Tel: +1 612 626 8862, Fax: +1 612 624 0315, Email: folso001{at}umn.edu

Aims: Recent studies showed that polymorphisms on chromosome 9p21 are associated with coronary heart disease (CHD), but few studies examined the association with heart failure (HF), stroke, or other subclinical atherosclerotic diseases. We tested the association of chromosome 9p21 polymorphisms with non-coronary atherosclerotic diseases.

Methods and results: We studied 4018 African-American and 11 085 white participants from the Atherosclerosis Risk in Communities Study, aged 45–64 at baseline (1987–89). We examined associations of rs10757274 and rs2383206 polymorphisms with incident HF through 2005 and ischaemic stroke through 2004, and with prevalent carotid atherosclerosis and peripheral artery disease (PAD) at baseline. The GG genotype of rs10757274 was associated with increased HF risk for whites. This association seemed independent of the established link between rs10757274 and clinical CHD, although an impact of rs10757274 on subclinical CHD leading to HF is not eliminated. Among whites, GG homozygotes were at weakly increased carotid atherosclerosis risk. There seemed to be no associations for ischaemic stroke or PAD. The results were essentially similar for rs2383206.

Conclusion: The GG genotype of rs10757274 on chromosome 9p21, which has been shown to increase CHD risk, is also associated with increased HF risk among whites. It is weakly or not associated with several other atherosclerosis outcomes.

Key Words: Epidemiology • Cohort study • Genetics • Congestive heart failure • Atherosclerosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.